TGFB1 and neoplasm: Mice with s.c. growing, advanced MC38 tumors (approximately 50 mm3 at the time of the therapy starting), were treated with lentiviral vectors carrying sequences of shRNA targeting TGF-β1 (shTGFβ1-1 LVs) or their combination with BMDC-based vaccines according to the scheme presented in the Figure 4A. Before application, the ex vivo differentiated BMDCs were stimulated with MC38 tumor lysate (BMDC/TAg).